A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)

Phase 2 Completed 18 enrolled Supernus Pharmaceuticals, Inc.

Non-randomizedSequentialOpen-labelTreatment

Summary

The primary purpose of this two-part study was to evaluate the safety and tolerability of SAGE-718 and its effects on cognitive, neuropsychiatric, and motor symptoms in participants with Parkinson's disease mild cognitive impairment (PD-MCI).

Timeline

Start: 2020-07-31
Primary completion: 2022-03-25
Completion: 2022-03-25

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dalzanemdor	Small molecule	3 mg	Oral

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)

Summary

Timeline

Drugs

Indications